American Cancer Society report also finds Black men continue to die from prostate cancer at twice the rate of White men
Tag: Prostate Cancer
Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended Treatments, Study Finds
Many U.S. doctors aren’t using the recommended initial treatments for their patients with hormone-sensitive metastatic prostate cancer, a new study has found. Often, it’s because they aren’t up to date on the latest treatment recommendations or because of side effect concerns.
Healthy diet may reduce the risk of low‐grade prostate cancer progressing to a higher grade
Cancer, Volume 131, Issue 4, 15 February 2025.
Healthy diet may reduce the risk of low‐grade prostate cancer progressing to a higher grade
Cancer, Volume 131, Issue 4, 15 February 2025.
[ASAP] Development and Evaluation of Novel 68Ga/177Lu-Labeled PSMA Inhibitors with Enhanced Pharmacokinetics and Tumor Imaging for Prostate Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.4c01302
[Articles] Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
The addition of [177Lu] Lu-PSMA-617 to enzalutamide was associated with improved survival and some aspects of HRQOL in patients with high-risk metastatic castration-resistant prostate cancer. Our findings warrant phase 3 evaluation of adaptive-dosed [177Lu] Lu-PSMA-617 in combination with androgen receptor pathway inhibitors in people with metastatic prostate cancer.
Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials
The SAKK 09/10 trial randomized biochemically-recurrent prostate cancer patients to salvage radiation 64Gy vs. 70Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive radiation 70.2Gy vs. 79.2Gy. We investigated a previously developed Post-Operative Radiation Therapy Outcomes Score (PORTOS) to identify preferential benefit from radiation dose escalation (DE).
Comment on: A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 years results of the OPERA trial
Neoadjuvant treatment has revolutionized the management of localized rectal cancer, by reducing the incidence of local and distant recurrences, by downstaging the tumor and expanding the indication to surgery, and by allowing watch-and-wait strategy in selected patients with complete clinical and radiological responses.
Short-course radiation therapy effective for endometrial cancer patients
Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.
Alarming rise in rates of advanced prostate cancer in California
The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.